IDYA IDEAYA Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IDYA

Price (delayed)

$41.49

Market cap

$3.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.96

Enterprise value

$2.94B

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates ...

Highlights
IDEAYA Biosciences's equity has surged by 78% YoY and by 22% QoQ
The quick ratio has soared by 69% YoY
The company's debt rose by 37% QoQ but it fell by 18% YoY
The net income has plunged by 93% YoY and by 9% from the previous quarter
The company's gross profit has shrunk by 54% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ideayabio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IDYA
Market
Shares outstanding
74.56M
Market cap
$3.09B
Enterprise value
$2.94B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.31
Price to sales (P/S)
102.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
125.66
Earnings
Revenue
$23.39M
EBIT
-$112.96M
EBITDA
-$108.95M
Free cash flow
-$117.59M
Per share
EPS
-$1.96
Free cash flow per share
-$2.04
Book value per share
$9.64
Revenue per share
$0.41
TBVPS
$11.29
Balance sheet
Total assets
$649.32M
Total liabilities
$28.23M
Debt
$2.87M
Equity
$621.09M
Working capital
$505.53M
Liquidity
Debt to equity
0
Current ratio
19.65
Quick ratio
19.4
Net debt/EBITDA
1.42
Margins
EBITDA margin
-465.9%
Gross margin
100%
Net margin
-483%
Operating margin
-574.9%
Efficiency
Return on assets
-21.8%
Return on equity
-23%
Return on invested capital
-30.2%
Return on capital employed
-18.2%
Return on sales
-483%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IDYA stock price

How has the IDEAYA Biosciences stock price performed over time
Intraday
0.75%
1 week
7.43%
1 month
-0.02%
1 year
114.31%
YTD
16.61%
QTD
-5.45%

Financial performance

How have IDEAYA Biosciences's revenue and profit performed over time
Revenue
$23.39M
Gross profit
$23.39M
Operating income
-$134.43M
Net income
-$112.96M
Gross margin
100%
Net margin
-483%
IDYA's operating income has dropped by 115% year-on-year and by 13% since the previous quarter
The net income has plunged by 93% YoY and by 9% from the previous quarter
The company's gross profit has shrunk by 54% YoY
The revenue has dropped by 54% year-on-year

Growth

What is IDEAYA Biosciences's growth rate over time

Valuation

What is IDEAYA Biosciences stock price valuation
P/E
N/A
P/B
4.31
P/S
102.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
125.66
The EPS has declined by 38% year-on-year
The stock's P/B is 96% above its 5-year quarterly average of 2.2 and 49% above its last 4 quarters average of 2.9
IDEAYA Biosciences's equity has surged by 78% YoY and by 22% QoQ
The stock's price to sales (P/S) is 105% more than its last 4 quarters average of 49.9
The revenue has dropped by 54% year-on-year

Efficiency

How efficient is IDEAYA Biosciences business performance
The ROA has contracted by 39% YoY but it has grown by 4.4% from the previous quarter
IDYA's ROIC is down by 36% YoY but it is up by 3.5% from the previous quarter
The company's return on equity fell by 25% YoY but it rose by 6% QoQ
The return on sales has declined by 10% since the previous quarter

Dividends

What is IDYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IDYA.

Financial health

How did IDEAYA Biosciences financials performed over time
The quick ratio has soared by 69% YoY
IDYA's current ratio has soared by 68% YoY
The company's debt is 100% lower than its equity
IDEAYA Biosciences's debt to equity has shrunk by 100% YoY
IDEAYA Biosciences's equity has surged by 78% YoY and by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.